Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

April 2012

Clinical Trials, Cohort Studies, Pilot Studies

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. Kim SR, El-Shamy A, Imoto S, et al. J Gastroenterol. 2012 Mar 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22441534.1

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. Larrey D, Lohse AW, de Ledinghen V, et al. J Hepatol. 2012 Mar 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22414766.1

The Cyclophilin Inhibitor SCY-635 Suppresses Viral Replication and Induces Endogenous Interferons in Patients With Chronic HCV Genotype 1 Infection. Hopkins S, Dimassimo B, Rusnak P, et al. J Hepatol. 2012 Mar 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22425702.1

An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Ogawa E, Furusyo N, Kajiwara E, et al. J Infect Chemother. 2012 Mar 27. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22450877.1

Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.

de Bruijne J, van Vliet A, Weegink CJ, et al. Antivir Ther. 2012 Mar 16. doi: 10.3851/IMP2078. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22427481.1

Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. Chojkier M, Elkhayat H, Sabry D, Donohue M, Buck M. PLoS One. 2012;7(3):e31516. Epub 2012 Mar 7.

http://www.ncbi.nlm.nih.gov/pubmed/22412837.1

Basic and Applied Science, Pre-Clinical Studies

Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus.

Lam AM, Espiritu C, Bansal S, et al. Antimicrob Agents Chemother. 2012 Mar 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22430955.1

Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. Kobayashi M, Suzuki F, Akuta N, et al. J Gastroenterol. 2012 Mar 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22438096.1

Detection of IL28B SNP DNA from Buccal Epithelial Cells, Small Amounts of Serum, and Dried Blood Spots. Halfon P, Ouzan D, Khiri H, et al. PLoS One. 2012;7(3):e33000. Epub 2012 Mar 7.

http://www.ncbi.nlm.nih.gov/pubmed/22412970.1

Patients with chronic hepatitis C express a high percentage of CD4(+)CXCR5 (+) T follicular helper cells. Feng J, Hu X, Guo H, et al. J Gastroenterol. 2012 Mar 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22426636.1

Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Varchetta S, Mele D, Mantovani S, et al. Hepatology. 2012 Mar 20. doi: 10.1002/hep.25723. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22431186.1

Hepatitis C Virus activates mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. Bose SK, Shrivastava S, Meyer K, Ray RB, Ray R. J Virol. 2012 Mar 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22457523.1

NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner.

Glässner A, Eisenhardt M, Krämer B, et al. Lab Invest. 2012 Mar 26. doi: 10.1038/ labinvest.2012.54. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22449797.1

Interferon α-Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. Stegmann KA, Björkström NK, Ciesek S, et al. J Infect Dis. 2012 Mar 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22457290

Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. Zeng Y, Li W, Li J, et al. Arch Virol. 2012 Mar 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22426896.1

HIV/HCV Coinfection

Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients. Laguno M, Martínez-Rebollar M, Perez I, et al. AIDS Res Hum Retroviruses. 2012 Mar 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22428909.1

Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. Vermehren J, Vermehren A, Mueller A, et al. BMC Gastroenterol. 2012 Mar 27;12(1):27. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22453133.1

Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection. Chary A, Winters MA, Eisen R, et al. J Med Virol. 2012 Mar;84(3):431-7. doi: 10.1002/jmv.23210.

http://www.ncbi.nlm.nih.gov/pubmed/22246828.1

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. Di Biagio A, Rosso R, Loregian A, et al. J Infect Chemother. 2012 Mar 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22422300.1

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Li Vecchi V, Soresi M, Giannitrapani L, et al. Int J Infect Dis. 2012 Mar 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22425495.1

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. Arribas J, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. HIV Med. 2012 Mar 14. doi: 10.1111/j.1468-1293.2012.00989.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22413874.1

Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. Bambha K, Pierce C, Cox C, et al. AIDS. 2012 Mar 13;26(5):599-607.

http://www.ncbi.nlm.nih.gov/pubmed/22156972.1

Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients. Guzmán-Fulgencio M, Jiménez JL, Berenguer J, et al. Antimicrob Chemother. 2012 Mar 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22156972.1

Impact of Hepatitis C Viral Clearance on CD4(+) T-Lymphocyte Course in HIV/HCV-Coinfected Patients Treated with Pegylated Interferon Plus Ribavirin. Milazzo L, Foschi A, Mazzali C, et al. AIDS Res Hum Retroviruses. 2012 Mar 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22220723.1

Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. Dominguez S, Ghosn J, Cassard B, et al. J Antimicrob Chemother. 2012 Mar 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22396433.1

Epidemiology, Diagnostics, and Miscellaneous Works

Rapid Decline of Liver Stiffness Following Alcohol Withdrawal in Heavy Drinkers. Trabut JB, Thépot V, Nalpas B, et al. Alcohol Clin Exp Res. 2012 Mar 8. doi: 10.1111/j.1530-0277.2012.01737.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22404692.1

Estimates of the Population Prevalence of Injection Drug Users among Hispanic Residents of Large US Metropolitan Areas. Pouget ER, Friedman SR, Cleland CM, Tempalski B, Cooper HL. J Urban Health. 2012 Mar 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22411420.1

The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco. Hermanstyne K, Bangsberg DR, Hennessey K, Weinbaum C, Hahn JA. J Public Health (Oxf). 2012 Mar 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22451327.1

Trends in the Prevalence of Thrombocytopenia among Individuals Infected with Hepatitis C Virus in the United States, 1999-2008. Kauf TL, Nelson DR, Schelfhout J, Delaney JA, Wang PF. BMC Res Notes. 2012 Mar 13;5(1):142. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22414142.1

Cost-Effectiveness and Population Outcomes of General Population Screening for Hepatitis C. Coffin PO, Scott JD, Golden MR, Sullivan SD. Clin Infect Dis. 2012 Mar 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22412061.1

Nutritional status in patients with hepatitis C. Ismail FW, Khan RA, Kamani L, et al. J Coll Physicians Surg Pak. 2012 Mar;22(3):139-42.

http://www.ncbi.nlm.nih.gov/pubmed/22414351.1

Liver Cancer

Role of IL28B Polymorphism in the Development of Hepatitis C Virus-Induced Hepatocellular Carcinoma, Graft Fibrosis, and Posttransplant Antiviral Therapy.

Eurich D, Boas-Knoop S, Bahra M, et al. Transplantation. 2012 Mar 27;93(6):644-9.

http://www.ncbi.nlm.nih.gov/pubmed/22411462.1

MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Augello C, Vaira V, Caruso L, et al. Liver Int. 2012 Mar 19. doi: 10.1111/j.1478-3231.2012.02795.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22429613.1

Combination PEG-IFN a-2b/Ribavirin Therapy Following Treatment of Hepatitis C Virus-Associated Hepatocellular Carcinoma is Capable of Improving Hepatic Functional Reserve and Survival. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T. Hepatogastroenterology. 2012 Mar-Apr;59(114):529-32. doi: 10.5754/hge10867.

http://www.ncbi.nlm.nih.gov/pubmed/22024226.1

Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C? Michielsen P, Ho E, Francque S. Minerva Gastroenterol Dietol. 2012 Mar;58(1):65-79.

http://www.ncbi.nlm.nih.gov/pubmed/22419005.1

Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma. Shitani M, Sasaki S, Akutsu N, et al. Tumour Biol. 2012 Mar 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22457049.1